Technical Corner
If You Think the Selling Started Yesterday, You Have a Short Memory
A lot of what we saw on Wednesday has been in the works for a while now.
Walgreens Boots Alliance Rallies Ahead of Earnings
Has WBA rallied too much?
Apple Earnings Land After Close -- Here's What the Charts Say
This is what I see going into the release of AAPL's quarterly report.
Tesla's Got You Revved Up Ahead of Earnings? Slow Down a Bit ...
All eyes will be on Wednesday night's report, but here's what the charts tell me -- and why you might consider tapping the brakes on long exposure.
Facebook's Sideways Trading Range Is Coming to an End
Let's review the charts and indicators.
Are Clouds Gathering for This Market?
S&P 500 breadth remains on bearish divergence.
Altria Stock Is Ready to Light Up
Earnings for the tobacco company are set for Thursday.
Allegheny Technologies Looks Headed Higher Ahead of Earnings
The charts and indicators of the metals producer are positive going into its fourth-quarter results.
Johnson & Johnson Rates Higher Price Targets Based on Its Charts
Buyers of the healthcare giant's shares have been more aggressive as the company pushes to launch its own Covid-19 vaccine.
Underperforming Transports, Vaccine Delivery, FOMC Statement, 3 Trading Thoughts
Wednesday afternoon the Fed's Federal Open Market Committee will publish the central bank's first official policy statement of 2021.
Keep Your Eyes on the Speculation Sideshow
I can't say when the market's B-movie will matter, but here's what I can tell you based on the indicators.
Is Live Ventures Taking Notes From GameStop?
Let's see what we might glean from the charts.
Ranpak Holdings May Double or More in 2021
Here's what aggressive traders should look for.
Let's Dare to Take Another Look at GameStop
Here's what we found in the latest GME charts.
Shark Bites: Stalking a Space SPAC
New Providence Acquisition's chart looks poor right now, but this name is on my radar, and I'm starting to build a position.
How Far Can Traders Go 'Beyond' This Pepsi Deal?
Beyond Meat is rising after a partnership with Pepsi was announced. Let's check the charts.
Abbott Labs Has the Formula for a Long Trade
ABT has made an upside breakout on the daily Point and Figure chart, and here's how investors can make their next move.
$55 Is the Make or Break Price for Crude Oil
It's difficult to imagine oil moving higher from here without significant help from further weakening in the greenback.
The Housing Market Is Hot and Home Depot Is Poised to Make New Highs
We're in the middle of one of the best housing markets ever as people upgrade to homes away from cities.
Could Johnson & Johnson Go Higher and Higher?
Will the vaccine will be a game changer? The charts are giving indications that J&J is ready to run.
Clorox Is Ready to Clean Up as the Downtrend Has Been Broken
Let's review the charts and indicators.
An Entertainment Giant and a Big Drugmaker Present Buy Setups
The stocks of Walt Disney Co. and Pfizer seem to offer nice upside potential based on their technical patterns.
Boot Barn Is Kickin' It, but Wait for a Correction to Saddle Up
The indicators for the western apparel retailer are bullish, but prices are extended compared to the longer-term moving averages, so be cautious.
How's the Market? (Well, My Mother Hasn't Called About It Yet)
Let's pick apart the wild ride on Monday -- how the selling dried up as soon as the move down -- and see what it all means.
General Electric Isn't Out of the Woods Yet, Here's How I'd Trade it
GE remains a cash flow based story, but I see two negatives.
S&P 500 Divergence Raises Concern
Market psychology remains cautionary.
Volatile Road Ahead, 4 Market Impact Thoughts, Monster Earnings Week
What can be done? Well for one, we are going to have to be creative. Jay, and Janet, I need you both paying attention here.
Bearish Bets: 2 NYSE Stocks You Should Consider Shorting This Week
These names are displaying both quantitative and technical deterioration.
AMC Is a High Risk, High Reward Play
Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.
GoodRx Needs a Shot in the Arm to Improve Its Outlook
IPOs in recent months have done extremely well -- not so GDRX.